JP7427253B2 - 環状一本鎖抗体 - Google Patents
環状一本鎖抗体 Download PDFInfo
- Publication number
- JP7427253B2 JP7427253B2 JP2020530175A JP2020530175A JP7427253B2 JP 7427253 B2 JP7427253 B2 JP 7427253B2 JP 2020530175 A JP2020530175 A JP 2020530175A JP 2020530175 A JP2020530175 A JP 2020530175A JP 7427253 B2 JP7427253 B2 JP 7427253B2
- Authority
- JP
- Japan
- Prior art keywords
- scfv
- cyclic
- tras
- chain antibody
- single chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 125000004122 cyclic group Chemical group 0.000 claims description 115
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 82
- 230000017730 intein-mediated protein splicing Effects 0.000 claims description 50
- 238000000034 method Methods 0.000 claims description 45
- 150000001413 amino acids Chemical class 0.000 claims description 41
- 230000027455 binding Effects 0.000 claims description 28
- 239000000427 antigen Substances 0.000 claims description 24
- 102000036639 antigens Human genes 0.000 claims description 24
- 108091007433 antigens Proteins 0.000 claims description 24
- 238000006243 chemical reaction Methods 0.000 claims description 21
- 108090000279 Peptidyltransferases Proteins 0.000 claims description 20
- 125000000539 amino acid group Chemical group 0.000 claims description 12
- 239000003814 drug Substances 0.000 claims description 4
- 239000007864 aqueous solution Substances 0.000 claims 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 64
- 125000002015 acyclic group Chemical group 0.000 description 39
- 238000007363 ring formation reaction Methods 0.000 description 39
- 108090000623 proteins and genes Proteins 0.000 description 37
- 239000000243 solution Substances 0.000 description 37
- 125000005647 linker group Chemical group 0.000 description 34
- 239000011780 sodium chloride Substances 0.000 description 32
- 102000004169 proteins and genes Human genes 0.000 description 30
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 29
- 235000018102 proteins Nutrition 0.000 description 26
- 238000004519 manufacturing process Methods 0.000 description 25
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 24
- 102000004196 processed proteins & peptides Human genes 0.000 description 24
- 239000000872 buffer Substances 0.000 description 23
- 238000005259 measurement Methods 0.000 description 23
- 235000001014 amino acid Nutrition 0.000 description 21
- 229940024606 amino acid Drugs 0.000 description 21
- 229920001184 polypeptide Polymers 0.000 description 21
- 241000588724 Escherichia coli Species 0.000 description 20
- 239000013612 plasmid Substances 0.000 description 18
- 108090000250 sortase A Proteins 0.000 description 18
- 239000013598 vector Substances 0.000 description 18
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 17
- 239000004471 Glycine Substances 0.000 description 16
- 210000004027 cell Anatomy 0.000 description 15
- 239000002609 medium Substances 0.000 description 15
- 102000005720 Glutathione transferase Human genes 0.000 description 14
- 108010070675 Glutathione transferase Proteins 0.000 description 14
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 14
- 108020004414 DNA Proteins 0.000 description 13
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 12
- 241000894006 Bacteria Species 0.000 description 12
- 239000007995 HEPES buffer Substances 0.000 description 12
- 238000001042 affinity chromatography Methods 0.000 description 12
- 229960000723 ampicillin Drugs 0.000 description 12
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 12
- 238000010586 diagram Methods 0.000 description 12
- 238000000502 dialysis Methods 0.000 description 12
- 239000012634 fragment Substances 0.000 description 12
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 12
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 12
- 239000004475 Arginine Substances 0.000 description 11
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 11
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 11
- 235000009697 arginine Nutrition 0.000 description 11
- 108091005804 Peptidases Proteins 0.000 description 10
- 239000000385 dialysis solution Substances 0.000 description 10
- 238000001641 gel filtration chromatography Methods 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- 239000004365 Protease Substances 0.000 description 9
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 9
- 238000009826 distribution Methods 0.000 description 9
- 238000002296 dynamic light scattering Methods 0.000 description 9
- 239000006228 supernatant Substances 0.000 description 9
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 8
- 102000001189 Cyclic Peptides Human genes 0.000 description 8
- 108010069514 Cyclic Peptides Proteins 0.000 description 8
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 8
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 238000010828 elution Methods 0.000 description 8
- 235000013922 glutamic acid Nutrition 0.000 description 8
- 239000004220 glutamic acid Substances 0.000 description 8
- 229960004198 guanidine Drugs 0.000 description 8
- 235000004400 serine Nutrition 0.000 description 8
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 7
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 7
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 7
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 7
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 7
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 7
- 235000004279 alanine Nutrition 0.000 description 7
- 108020004707 nucleic acids Proteins 0.000 description 7
- 150000007523 nucleic acids Chemical class 0.000 description 7
- 102000039446 nucleic acids Human genes 0.000 description 7
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 7
- 235000008729 phenylalanine Nutrition 0.000 description 7
- 229960000575 trastuzumab Drugs 0.000 description 7
- 108010053070 Glutathione Disulfide Proteins 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 238000004108 freeze drying Methods 0.000 description 6
- YPZRWBKMTBYPTK-BJDJZHNGSA-N glutathione disulfide Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@H](C(=O)NCC(O)=O)CSSC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O YPZRWBKMTBYPTK-BJDJZHNGSA-N 0.000 description 6
- 229930027917 kanamycin Natural products 0.000 description 6
- 229960000318 kanamycin Drugs 0.000 description 6
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 6
- 229930182823 kanamycin A Natural products 0.000 description 6
- YPZRWBKMTBYPTK-UHFFFAOYSA-N oxidized gamma-L-glutamyl-L-cysteinylglycine Natural products OC(=O)C(N)CCC(=O)NC(C(=O)NCC(O)=O)CSSCC(C(=O)NCC(O)=O)NC(=O)CCC(N)C(O)=O YPZRWBKMTBYPTK-UHFFFAOYSA-N 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 229960005322 streptomycin Drugs 0.000 description 6
- 239000000758 substrate Substances 0.000 description 6
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 5
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 5
- 239000006142 Luria-Bertani Agar Substances 0.000 description 5
- 101710175625 Maltose/maltodextrin-binding periplasmic protein Proteins 0.000 description 5
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 5
- 238000004220 aggregation Methods 0.000 description 5
- 230000002776 aggregation Effects 0.000 description 5
- 230000001580 bacterial effect Effects 0.000 description 5
- 238000003776 cleavage reaction Methods 0.000 description 5
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 5
- 235000018417 cysteine Nutrition 0.000 description 5
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 5
- 235000013930 proline Nutrition 0.000 description 5
- 239000012146 running buffer Substances 0.000 description 5
- 230000007017 scission Effects 0.000 description 5
- 238000000527 sonication Methods 0.000 description 5
- 238000003860 storage Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 4
- 244000063299 Bacillus subtilis Species 0.000 description 4
- 235000014469 Bacillus subtilis Nutrition 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 4
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 4
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 4
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 4
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 4
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 4
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 4
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 4
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 4
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 4
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 4
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 4
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 4
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 4
- 239000004472 Lysine Substances 0.000 description 4
- 108010033276 Peptide Fragments Proteins 0.000 description 4
- 102000007079 Peptide Fragments Human genes 0.000 description 4
- 102100027913 Peptidyl-prolyl cis-trans isomerase FKBP1A Human genes 0.000 description 4
- 108010006877 Tacrolimus Binding Protein 1A Proteins 0.000 description 4
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 4
- 239000004473 Threonine Substances 0.000 description 4
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 4
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- 108010013829 alpha subunit DNA polymerase III Proteins 0.000 description 4
- 235000009582 asparagine Nutrition 0.000 description 4
- 229960001230 asparagine Drugs 0.000 description 4
- 235000003704 aspartic acid Nutrition 0.000 description 4
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 4
- 238000010367 cloning Methods 0.000 description 4
- 238000012258 culturing Methods 0.000 description 4
- 108020001507 fusion proteins Proteins 0.000 description 4
- 102000037865 fusion proteins Human genes 0.000 description 4
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 4
- 235000004554 glutamine Nutrition 0.000 description 4
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 4
- 235000014304 histidine Nutrition 0.000 description 4
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 4
- 229960000310 isoleucine Drugs 0.000 description 4
- 235000018977 lysine Nutrition 0.000 description 4
- 229930182817 methionine Natural products 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 238000005063 solubilization Methods 0.000 description 4
- 230000007928 solubilization Effects 0.000 description 4
- 239000011537 solubilization buffer Substances 0.000 description 4
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 4
- 235000002374 tyrosine Nutrition 0.000 description 4
- 239000004474 valine Substances 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- 229920000936 Agarose Polymers 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 241001198387 Escherichia coli BL21(DE3) Species 0.000 description 3
- 241000238631 Hexapoda Species 0.000 description 3
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 3
- 241000424623 Nostoc punctiforme Species 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- 125000003277 amino group Chemical group 0.000 description 3
- 239000007853 buffer solution Substances 0.000 description 3
- 210000004900 c-terminal fragment Anatomy 0.000 description 3
- 210000004899 c-terminal region Anatomy 0.000 description 3
- 229960005091 chloramphenicol Drugs 0.000 description 3
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 3
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 3
- 230000003100 immobilizing effect Effects 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 210000004898 n-terminal fragment Anatomy 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- 239000011347 resin Substances 0.000 description 3
- 229920005989 resin Polymers 0.000 description 3
- 230000000717 retained effect Effects 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 238000000108 ultra-filtration Methods 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 108010005094 Advanced Glycation End Products Proteins 0.000 description 2
- 102000004400 Aminopeptidases Human genes 0.000 description 2
- 108090000915 Aminopeptidases Proteins 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 2
- 108010024636 Glutathione Proteins 0.000 description 2
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 2
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 2
- 229930064664 L-arginine Natural products 0.000 description 2
- 235000014852 L-arginine Nutrition 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 108010020062 Peptidylprolyl Isomerase Proteins 0.000 description 2
- 102000009658 Peptidylprolyl Isomerase Human genes 0.000 description 2
- 108091081024 Start codon Proteins 0.000 description 2
- 101710154918 Trigger factor Proteins 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 229910001424 calcium ion Inorganic materials 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 239000012149 elution buffer Substances 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 238000011067 equilibration Methods 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 239000012460 protein solution Substances 0.000 description 2
- 230000016434 protein splicing Effects 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000012134 supernatant fraction Substances 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- 239000013638 trimer Substances 0.000 description 2
- 239000011534 wash buffer Substances 0.000 description 2
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 241000186361 Actinobacteria <class> Species 0.000 description 1
- 241000203069 Archaea Species 0.000 description 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
- 102000005367 Carboxypeptidases Human genes 0.000 description 1
- 108010006303 Carboxypeptidases Proteins 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 241000192700 Cyanobacteria Species 0.000 description 1
- 102000001493 Cyclophilins Human genes 0.000 description 1
- 108010068682 Cyclophilins Proteins 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 241000620209 Escherichia coli DH5[alpha] Species 0.000 description 1
- 241000701959 Escherichia virus Lambda Species 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 102000018389 Exopeptidases Human genes 0.000 description 1
- 108010091443 Exopeptidases Proteins 0.000 description 1
- 102000009127 Glutaminase Human genes 0.000 description 1
- 108010073324 Glutaminase Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 101001128814 Pandinus imperator Pandinin-1 Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 108010027179 Tacrolimus Binding Proteins Proteins 0.000 description 1
- 102000018679 Tacrolimus Binding Proteins Human genes 0.000 description 1
- 108020005038 Terminator Codon Proteins 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 102100036407 Thioredoxin Human genes 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 238000012219 cassette mutagenesis Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- -1 for example Chemical class 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000003402 intramolecular cyclocondensation reaction Methods 0.000 description 1
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 108010091748 peptide A Proteins 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 108060008226 thioredoxin Proteins 0.000 description 1
- 229940094937 thioredoxin Drugs 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/06—Preparation of peptides or proteins produced by the hydrolysis of a peptide bond, e.g. hydrolysate products
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/22—Cysteine endopeptidases (3.4.22)
- C12Y304/22007—Asclepain (3.4.22.7)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/22—Cysteine endopeptidases (3.4.22)
- C12Y304/2207—Sortase A (3.4.22.70)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Description
[A-1]重鎖可変領域(VH)および軽鎖可変領域(VL)が第1のペプチドリンカーで連結された一本鎖抗体(scFv)において、そのN末端とC末端が第2のペプチドリンカーで連結されている、環状一本鎖抗体。
[A-2]第2のペプチドリンカーがトランスペプチダーゼにより形成される、[A-1]に記載の環状一本鎖抗体。
[A-3]トランスペプチダーゼがソルターゼである、[A-2]に記載の環状一本鎖抗体。
[A-4]第2のペプチドリンカーがアミノ酸配列:LPXTG(ここで、Xは任意のアミノ酸残基を表す)を含む、[A-1]~[A-3]のいずれかに記載の環状一本鎖抗体。
[A-5]第1のペプチドリンカーが15~27個のアミノ酸からなる、[A-1]~[A-4]のいずれかに記載の環状一本鎖抗体。
[A-6]第2のペプチドリンカーが19~28個のアミノ酸からなる、[A-1]~[A-5]のいずれかに記載の環状一本鎖抗体。
[A-7]重鎖可変領域(VH)および軽鎖可変領域(VL)が同一で非環状の一本鎖抗体と比較して、保存時の凝集性が抑制されている、[A-1]~[A-6]のいずれかに記載の環状一本鎖抗体。
[A-8][A-1]~[A-7]のいずれかに記載の環状一本鎖抗体の製造方法であって、
1)重鎖可変領域(VH)および軽鎖可変領域(VL)が第1のペプチドリンカーで連結された一本鎖抗体(scFv)であって、N末端およびC末端にトランスペプチダーゼ認識配列を有する非環状一本鎖抗体を調製する工程;
2)トランスペプチダーゼを用いて前記一本鎖抗体のN末端およびC末端のトランスペプチダーゼ認識配列から第2のペプチドリンカーを形成し、前記一本鎖抗体を環化する工程
を含む、前記製造方法。
[A-9]トランスペプチダーゼがソルターゼである、[A-8]に記載の製造方法。
[A-10]非環状一本鎖抗体のN末端のトランスペプチダーゼ認識配列がLPXTG(ここで、Xは任意のアミノ酸残基を表す)を含む、[A-8]または[A-9]に記載の製造方法。
[A-11]非環状一本鎖抗体のC末端のトランスペプチダーゼ認識配列がGGを含む、[A-8]~[A-10]のいずれかに記載の製造方法。
[B-1]重鎖可変領域(VH)および軽鎖可変領域(VL)が第1のペプチドリンカーで連結された一本鎖抗体(scFv)において、そのN末端とC末端が第2のペプチドリンカーで連結されている、環状一本鎖抗体。
[B-2]環状構造がペプチド結合のみで形成されている、[B-1]に記載の環状一本鎖抗体。
[B-3]VHとVLが分子内で会合して抗原結合部位を形成する、[B-1]または[B-2]に記載の環状一本鎖抗体。
[B-4]分子内に1つの抗原結合部位を有する、[B-1]~[B-3]のいずれかに記載の環状一本鎖抗体。
[B-5]第1のペプチドリンカーが15~27個のアミノ酸からなる、[B-1]~[B-4]のいずれかに記載の環状一本鎖抗体。
[B-6]第2のペプチドリンカーが15~28個のアミノ酸からなる、[B-1]~[B-5]のいずれかに記載の環状一本鎖抗体。
[B-7]VHおよびVLが同一で非環状の一本鎖抗体と比較して、凝集体形成が抑制されている、[B-1]~[B-6]のいずれかに記載の環状一本鎖抗体。
[B-8]第2のペプチドリンカーがトランスペプチダーゼにより形成される、[B-1]~[B-7]のいずれかに記載の環状一本鎖抗体。
[B-9]トランスペプチダーゼがソルターゼである、[B-8]に記載の環状一本鎖抗体。
[B-10]第2のペプチドリンカーがアミノ酸配列:LPXTG(ここで、Xは任意のアミノ酸残基を表す)を含む、[B-1]~[B-9]のいずれかに記載の環状一本鎖抗体。
[B-11]第2のペプチドリンカーがスプリットインテインによるトランス-スプライシング反応により形成される、[B-1]~[B-7]のいずれかに記載の環状一本鎖抗体。
[B-12][B-1]~[B-7]のいずれかに記載の環状一本鎖抗体の製造方法であって、
1)重鎖可変領域(VH)および軽鎖可変領域(VL)が第1のペプチドリンカーで連結された一本鎖抗体(scFv)であって、N末端およびC末端にトランスペプチダーゼ認識配列を有する非環状ペプチドを調製する工程;
2)トランスペプチダーゼを用いて前記一本鎖抗体のN末端およびC末端のトランスペプチダーゼ認識配列から第2のペプチドリンカーを形成し、前記一本鎖抗体を環化する工程
を含む、前記製造方法。
[B-13]トランスペプチダーゼがソルターゼである、[B-8]に記載の製造方法。
[B-14]非環状ペプチドのN末端のトランスペプチダーゼ認識配列がLPXTG(ここで、Xは任意のアミノ酸残基を表す)を含む、[B-12]または[B-13]に記載の製造方法。
[B-15]非環状ペプチドのC末端のトランスペプチダーゼ認識配列がGGを含む、[B-12]~[B-14]のいずれかに記載の製造方法。
[B-16][B-1]~[B-7]のいずれかに記載の環状一本鎖抗体の製造方法であって、
1)重鎖可変領域(VH)および軽鎖可変領域(VL)が第1のペプチドリンカーで連結された一本鎖抗体(scFv)であって、N末端にスプリットインテインのC末端側断片(Int-C)およびC末端にスプリットインテインのN末端側断片(Int-N)をそれぞれ有する非環状ペプチドを調製する工程;
2)スプリットインテインによるトランス-スプライシング反応により第2のペプチドリンカーを形成し、前記一本鎖抗体を環化する工程
を含む、前記製造方法。
[B-17]スプリットインテインのC末端側断片(Int-C)としてDnaE-Int-C、N末端側断片(Int-N)としてDnaE-Int-Nが用いられる、[B-16]に記載の製造方法。
[B-18][B-16]の工程1に記載の非環状ペプチドのアミノ酸配列をコードする塩基配列を含む核酸。
[B-19][B-18]に記載の核酸を含有する組換えベクター。
[B-20][B-19]に記載の組換えベクターを導入した形質転換体。
(1)scFvのN末端にグリシンを導入する。N末端にグリシンを有するタンパク質の作製は発現ホストに内在するアミノペプチダーゼを利用する、グリシンの前にTev Proteaseの認識配列 (ENLYFQ / G ただし、認識配列中の/は切断部位を示す) やHRV3Cプロテアーゼの認識配列 (LEVLFQ /GG ないしは LEVLFQ / GPただし、認識配列中の/は切断部位を示す)などのタンパク質分解酵素の切断配列を挿入しておくことで、タンパク質分解酵素で消化することでN末端にグリシンを有するscFvを作製することができる。
(2)(1)で例示される手順により作製されたN末端にグリシンを有し、C末端にLPXTG配列を含むscFvに対してソルターゼAを作用させることで環状scFvを作製することができる。中性付近 (pH 5.5~9.5)の緩衝液中で連結反応を行うこととなる。使用するソルターゼAによってはさらにカルシウムイオンを反応液中に添加することが必要となる。
(3)環状scFvを作製するのに用いるscFvの作製には大腸菌、酵母、哺乳細胞、昆虫細胞等を含むあらゆる宿主を用いることができ、プロモーターとしてはT7、Taq、lac等を含むあらゆるプロモーターを用いることができる。
可溶化バッファー : 6 M グアニジン-HCl, 25 mM リン酸塩 pH 7.4, 375 mM NaCl;
洗浄バッファー: 6 M グアニジン-HCl, 25 mM リン酸塩 pH 7.4, 375 mM NaCl, 10 mMイミダゾール;
溶出バッファー : 6 M グアニジン-HCl, 25 mM リン酸塩 pH 7.4, 375 mM NaCl, 250 mM イミダゾール。
1 日目 透析1回目: 透析外液:3 M Gdn-HCl バッファー: 1L;
2 日目 透析2回目: 透析外液 : 2/3 L + ベースバッファー : 1/3 L;
透析3回目: 1 M Gdn-HCl バッファー : 1 L + 375 μM 酸化型グルタチオン (ナカライテスク社);
3 日目 透析4回目: 透析外液 : 500 mL + 1 M Gdn-HCl バッファー: 500 mL + 375 μM 酸化型グルタチオン;
透析5回目: 透析外液 : 500 mL + アルギニンベースバッファー 500 mL + 375 μM 酸化型グルタチオン;
4 日目 透析6回目: 透析外液500 mL + アルギニンベースバッファー 500 mL + 375 μM 酸化型グルタチオン;
透析7回目: アルギニンベースバッファー : 1 L + 375 μM 酸化型グルタチオン;
5 日目 透析8回目:ベースバッファー : 1 L;
3 M Gdn-HCl バッファー: 3 M グアニジン-HCl, 50 mM Tris-HCl pH 7.5 @4℃, 200 mM NaCl, 1 mM EDTA;
1 M Gdn-HCl バッファー: 1 M グアニジン-HCl, 50 mM Tris-HCl pH 7.5 @4℃, 200 mM NaCl, 1 mM EDTA, 0.4 M L-アルギニン;
ベースバッファー: 50 mM Tris-HCl pH 7.5 @4℃, 200 mM NaCl, 1 mM EDTA
アルギニンベースバッファー: 50 mM Tris-HCl pH 7.5 @4℃, 200 mM NaCl, 1 mM EDTA, 0.4 M L-アルギニン;
レーン1:分子量マーカー;
レーン2:ソルターゼA;
レーン3:Y9-scFVにHRV3C proteaseを添加したもの;
レーン4:Y9-scFVにソルターゼAとHRV3C proteaseを添加したもの;
レーン5:環化反応後;
レーン6:Ni-NTAアフィニティークロマトグラフィーの素通り画分;
レーン7:洗浄画分;
レーン8:溶出画分。
レーン1:分子量マーカー;
レーン2:ソルターゼA;
レーン3:Tras-scFvにHRV3C proteaseを添加したもの;
レーン4:環状化反応後;
レーン5:Ni-NTAアフィニティークロマトグラフィーの素通り画分;
レーン6:洗浄画分;
レーン7:溶出画分
Claims (11)
- 重鎖可変領域(VH)および軽鎖可変領域(VL)が第1のペプチドリンカーで連結された一本鎖抗体(scFv)の水溶液中での該一本鎖抗体の分子間会合を抑制する方法であって、
該一本鎖抗体のN末端とC末端を第2のペプチドリンカーで連結して環状の一本鎖抗体に変換する工程、および
該環状の一本鎖抗体の水溶液を調製する工程
を含み、
環状の一本鎖抗体の環状構造がペプチド結合のみで形成されている、方法。 - 環状の一本鎖抗体のVHとVLが分子内で会合して抗原結合部位を形成する、請求項1に記載の方法。
- 環状の一本鎖抗体が分子内に1つの抗原結合部位を有する、請求項1または2に記載の方法。
- 第1のペプチドリンカーが15~27個のアミノ酸からなる、請求項1~3のいずれか1項に記載の方法。
- 第2のペプチドリンカーが15~28個のアミノ酸からなる、請求項1~4のいずれか1項に記載の方法。
- 前記水溶液が環状一本鎖抗体の凍結乾燥品を再構成して調製される、請求項1~5のいずれか1項に記載の方法。
- 第2のペプチドリンカーによる連結がトランスペプチダーゼにより形成される、請求項1~6のいずれか1項に記載の方法。
- トランスペプチダーゼがソルターゼである、請求項7に記載の方法。
- 第2のペプチドリンカーがアミノ酸配列:LPXTG(ここで、Xは任意のアミノ酸残基を表す)を含む、請求項1~8のいずれか1項に記載の方法。
- 第2のペプチドリンカーによる連結がスプリットインテインによるトランス-スプライシング反応により形成される、請求項1~6のいずれか1項に記載の方法。
- 前記水溶液が医薬品として使用される、請求項1~10のいずれか1項に記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2018130203 | 2018-07-09 | ||
JP2018130203 | 2018-07-09 | ||
PCT/JP2019/026983 WO2020013126A1 (ja) | 2018-07-09 | 2019-07-08 | 環状一本鎖抗体 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPWO2020013126A1 JPWO2020013126A1 (ja) | 2021-08-02 |
JP7427253B2 true JP7427253B2 (ja) | 2024-02-05 |
Family
ID=69143093
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020530175A Active JP7427253B2 (ja) | 2018-07-09 | 2019-07-08 | 環状一本鎖抗体 |
Country Status (4)
Country | Link |
---|---|
US (1) | US20210388112A1 (ja) |
EP (1) | EP3828200A4 (ja) |
JP (1) | JP7427253B2 (ja) |
WO (1) | WO2020013126A1 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020013126A1 (ja) * | 2018-07-09 | 2020-01-16 | 国立大学法人 熊本大学 | 環状一本鎖抗体 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100129807A1 (en) | 2007-01-10 | 2010-05-27 | Geyer Ronald C | Stabilization of cyclic peptide structures |
JP2016511279A (ja) | 2013-03-15 | 2016-04-14 | エヌビーイー セラピューティクス アクチェン ゲゼルシャフト | 免疫リガンド/ペイロード複合体の生産方法 |
WO2017024131A1 (en) | 2015-08-04 | 2017-02-09 | Avidbiotics Corp. | Insertable variable fragments of antibodies and modified a1-a2 domains of nkg2d ligands, and non-natural nkg2d ligands that bind non-natural nkg2d receptors |
WO2017222556A3 (en) | 2016-06-24 | 2018-04-19 | Avidbiotics Corp. | Insertable variable fragments of antibodies and modified a1-a2 domains of nkg2d ligands |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1294148C (zh) | 2001-04-11 | 2007-01-10 | 中国科学院遗传与发育生物学研究所 | 环状单链三特异抗体 |
US8940501B2 (en) | 2009-01-30 | 2015-01-27 | Whitehead Institute For Biomedical Research | Methods for ligation and uses thereof |
ES2597228T3 (es) | 2012-06-27 | 2017-01-17 | F. Hoffmann-La Roche Ag | Procedimiento para la selección y la producción de entidades de objetivación, como dianas, altamente selectivas y multiespecíficas, personalizadas, las cuales contienen por lo menos dos entidades de unión diferentes, y utilización de éstas |
MX2014014804A (es) | 2012-06-27 | 2015-02-12 | Hoffmann La Roche | Metodo para la elaboracion de conjugados de la region fc de anticuerpos que comprenden por lo menos una entidad de union que se une especificamente a un objetivo y usos del mismo. |
WO2014140361A1 (en) * | 2013-03-15 | 2014-09-18 | Takeda Gmbh | Formulation of an antibody and use thereof |
WO2016167291A1 (ja) | 2015-04-13 | 2016-10-20 | 国立研究開発法人産業技術総合研究所 | 環状化サイトカイン及びその製法 |
WO2020013126A1 (ja) * | 2018-07-09 | 2020-01-16 | 国立大学法人 熊本大学 | 環状一本鎖抗体 |
-
2019
- 2019-07-08 WO PCT/JP2019/026983 patent/WO2020013126A1/ja active Search and Examination
- 2019-07-08 JP JP2020530175A patent/JP7427253B2/ja active Active
- 2019-07-08 EP EP19833025.0A patent/EP3828200A4/en active Pending
- 2019-07-08 US US17/258,529 patent/US20210388112A1/en active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100129807A1 (en) | 2007-01-10 | 2010-05-27 | Geyer Ronald C | Stabilization of cyclic peptide structures |
JP2016511279A (ja) | 2013-03-15 | 2016-04-14 | エヌビーイー セラピューティクス アクチェン ゲゼルシャフト | 免疫リガンド/ペイロード複合体の生産方法 |
WO2017024131A1 (en) | 2015-08-04 | 2017-02-09 | Avidbiotics Corp. | Insertable variable fragments of antibodies and modified a1-a2 domains of nkg2d ligands, and non-natural nkg2d ligands that bind non-natural nkg2d receptors |
WO2017222556A3 (en) | 2016-06-24 | 2018-04-19 | Avidbiotics Corp. | Insertable variable fragments of antibodies and modified a1-a2 domains of nkg2d ligands |
Non-Patent Citations (2)
Title |
---|
van't HOF W. et al.,Sortase-mediated backbone cyclization of proteins and peptides,Biol. Chem., 2015 vol.396, no.4, p.283-293 |
YAMAUCHI S. et al.,Cyclization of Single-Chain Fv Antibodies Markedly Suppressed Their Characteristic Aggregation Mediated by Inter-Chain VH-VL Interactions,Molecules, 18 July 2019, vol.24, 2620(p.1-12) |
Also Published As
Publication number | Publication date |
---|---|
EP3828200A1 (en) | 2021-06-02 |
JPWO2020013126A1 (ja) | 2021-08-02 |
WO2020013126A1 (ja) | 2020-01-16 |
US20210388112A1 (en) | 2021-12-16 |
EP3828200A4 (en) | 2022-05-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2612166T3 (es) | Nuevas proteínas de unión a inmunoglobulina con especificidad mejorada | |
US20210206815A1 (en) | Alkaline stable fc-binding proteins for affinity chromatography | |
AU2016293063B2 (en) | Novel immunoglobulin-binding proteins and their use in affinity purification | |
CN103459415B (zh) | 设计的与血清白蛋白结合的重复蛋白 | |
CN111132994B (zh) | 在c末端螺旋区中具有半胱氨酸的fc结合蛋白 | |
WO2015030094A1 (ja) | Fab領域結合性ペプチド | |
CN112334149A (zh) | 在c末端螺旋区具有半胱氨酸的fc结合蛋白 | |
JP7427253B2 (ja) | 環状一本鎖抗体 | |
CN113045633B (zh) | 蛋白质异质缠结基元的设计与复杂索烃结构的制备方法 | |
JP2023533529A (ja) | アフィニティ精製のための免疫グロブリン結合タンパク質 | |
WO2021181111A1 (en) | System for covalently linking proteins | |
JP2022078884A (ja) | Peg化環状一本鎖抗体 | |
JP2022178934A (ja) | 二量体を形成する環状一本鎖抗体 | |
CN116621947B (zh) | 一种基于索烃骨架的拓扑蛋白质、制备方法及应用 | |
JP2023547340A (ja) | 新規ii型コラーゲン結合タンパク質 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210115 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220630 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230710 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20230908 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20231107 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20231206 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20231228 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20240115 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20240117 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7427253 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |